PURPOSE: Prior cross-sectional studies have shown that cancer patients have sleep-wake activity cycles that show little distinction between daytime and nighttime, a pattern indicative of circadian disruption. This pattern is seen both before and during cancer treatment. Long-term data are needed, however, to assess to what extent circadian rhythm impairments evolve over the course of chemotherapy. The goal of this study was to assess the longitudinal course of sleep-wake activity rhythms before and during chemotherapy for breast cancer. PATIENTS AND METHODS: Ninety-five women scheduled to receive neoadjuvant or adjuvant anthracycline based chemotherapy for a stage I-III breast cancer participated. The participants wore a wrist actigraph for 72 consecutive hours at baseline (pre-chemotherapy), as well as during the weeks 1, 2 and 3 (W1, W2, W3) of cycle 1 and cycle 4 of chemotherapy. Sleep-wake circadian activity variables were computed based on actigraphic data. RESULTS: Compared to baseline, with the exception of acrophase, all circadian rhythm variables examined, including amplitude, mesor, up-mesor, down-mesor, and rhythmicity were significantly impaired during the first week of both chemotherapy cycles. Although the circadian variables approached baseline values during W2 and W3 of cycle 1, most remained significantly more impaired during W2 and W3 of cycle 4. CONCLUSION: These data suggest that the first administration of chemotherapy is associated with transient disruption of sleep-wake rhythm, while repeated administration of chemotherapy results in progressively worse and more enduring impairments in sleep-wake activity rhythms.
PURPOSE: Prior cross-sectional studies have shown that cancerpatients have sleep-wake activity cycles that show little distinction between daytime and nighttime, a pattern indicative of circadian disruption. This pattern is seen both before and during cancer treatment. Long-term data are needed, however, to assess to what extent circadian rhythm impairments evolve over the course of chemotherapy. The goal of this study was to assess the longitudinal course of sleep-wake activity rhythms before and during chemotherapy for breast cancer. PATIENTS AND METHODS: Ninety-five women scheduled to receive neoadjuvant or adjuvant anthracycline based chemotherapy for a stage I-III breast cancer participated. The participants wore a wrist actigraph for 72 consecutive hours at baseline (pre-chemotherapy), as well as during the weeks 1, 2 and 3 (W1, W2, W3) of cycle 1 and cycle 4 of chemotherapy. Sleep-wake circadian activity variables were computed based on actigraphic data. RESULTS: Compared to baseline, with the exception of acrophase, all circadian rhythm variables examined, including amplitude, mesor, up-mesor, down-mesor, and rhythmicity were significantly impaired during the first week of both chemotherapy cycles. Although the circadian variables approached baseline values during W2 and W3 of cycle 1, most remained significantly more impaired during W2 and W3 of cycle 4. CONCLUSION: These data suggest that the first administration of chemotherapy is associated with transient disruption of sleep-wake rhythm, while repeated administration of chemotherapy results in progressively worse and more enduring impairments in sleep-wake activity rhythms.
Authors: M C Mormont; J Waterhouse; P Bleuzen; S Giacchetti; A Jami; A Bogdan; J Lellouch; J L Misset; Y Touitou; F Lévi Journal: Clin Cancer Res Date: 2000-08 Impact factor: 12.531
Authors: Paul J Mills; Barbara Parker; Vicky Jones; Karen A Adler; Christy J Perez; Sherella Johnson; Mairav Cohen-Zion; Matthew Marler; Georgia R Sadler; Joel E Dimsdale; Sonia Ancoli-Israel Journal: Clin Cancer Res Date: 2004-08-01 Impact factor: 12.531
Authors: Sonia Ancoli-Israel; Roger Cole; Cathy Alessi; Mark Chambers; William Moorcroft; Charles P Pollak Journal: Sleep Date: 2003-05-01 Impact factor: 5.849
Authors: Kathy P Parker; Donald L Bliwise; Maria Ribeiro; Sanjay R Jain; Catherine I Vena; Mary Kay Kohles-Baker; Andre Rogatko; Zhiheng Xu; Wayne B Harris Journal: J Clin Oncol Date: 2008-05-20 Impact factor: 44.544
Authors: Fay Wright; Gail D'Eramo Melkus; Marilyn Hammer; Brian L Schmidt; M Tish Knobf; Steven M Paul; Frances Cartwright; Judy Mastick; Bruce A Cooper; Lee-May Chen; Michelle Melisko; Jon D Levine; Kord Kober; Bradley E Aouizerat; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2015-03-28 Impact factor: 3.612
Authors: Stacy D Sanford; Lynne I Wagner; Jennifer L Beaumont; Zeeshan Butt; Jerry J Sweet; David Cella Journal: Support Care Cancer Date: 2012-10-03 Impact factor: 3.603
Authors: Christina Van Onselen; Bruce A Cooper; Kathryn Lee; Laura Dunn; Bradley E Aouizerat; Claudia West; Marylin Dodd; Steven Paul; Christine Miaskowski Journal: Support Care Cancer Date: 2012-10 Impact factor: 3.603
Authors: Andrea M Barsevick; Michael R Irwin; Pamela Hinds; Andrew Miller; Ann Berger; Paul Jacobsen; Sonia Ancoli-Israel; Bryce B Reeve; Karen Mustian; Ann O'Mara; Jin-Shei Lai; Michael Fisch; David Cella Journal: J Natl Cancer Inst Date: 2013-09-18 Impact factor: 13.506
Authors: Christina Van Onselen; Steven M Paul; Kathryn Lee; Laura Dunn; Bradley E Aouizerat; Claudia West; Marylin Dodd; Bruce Cooper; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2012-08-24 Impact factor: 3.612